Search
Firocoxib
go.drugbank.com/drugs/DB09217ExperimentalVet approvedFirocoxib was the first COX-2 inhibitor approved by the U.S. Food and Drug Administration for horses. Firocoxib is not intended or approved for use in human medicine. … Firocoxib is a cycooxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug. It currently approved for veterinary use in dogs and horses under the brand names Equioxx and Previcox.
Categories: Heterocyclic Compounds, 1-Ring, Selective Cyclooxygenase 2 Inhibitors (NSAIDs)N(4)-Adenosyl-N(4)-methyl-2,4-diaminobutanoic acid
go.drugbank.com/drugs/DB03458ExperimentalN(4)-adenosyl-n(4)-methyl-2,4-diaminobutanoic acid is a solid. This compound belongs to the purine nucleosides and analogues. These are compounds comprising a purine base attached to a sugar.
Synonyms: 5'-{[(3S)-3-Amino-3-carboxypropyl](methyl)amino}-5'-deoxyadenosine, N(4)-Adenosyl-N(4)-methyl-2,4-diaminobutanoic acidN-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide
go.drugbank.com/drugs/DB06945ExperimentalN-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxamide is a solid. This compound belongs to the diarylethers. … These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups.
Synonyms: N-hydroxy-4-({4-[4-(trifluoromethyl)phenoxy]phenyl}sulfonyl)tetrahydro-2H-pyran-4-carboxamideLomedeucitinib
go.drugbank.com/drugs/DB21649InvestigationalLomedeucitinib is a small molecule drug. The usage of the INN stem '-citinib' in the name indicates that Lomedeucitinib is a Janus kinase inhibitor. … Lomedeucitinib is under investigation in clinical trial NCT05730725 (A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe Psoriasis).
Parnaparin
go.drugbank.com/drugs/DB09260ApprovedParnaparin is an heparin of low molecular weight with antithrombotic effects.
Products: FLUXUM 0.3 ML 3200 IU 2 HAZIR SIRINGA, FLUXUM 0.3 ML 3200 IU 6 HAZIR SIRINGAInbakicept
go.drugbank.com/drugs/DB16479InvestigationalIt is one of the active ingredients in Anktiva, a combination product also containing [nogapendekin alfa], where a single inbakicept is complexed with two nogapendekin alfa components. … [A263617, A263622] Inbakicept, in combination with nogapendekin alfa, mimics the actions of IL-15, stimulating the activation and proliferation of natural killer cells and CD8+ memory T cells, which also
Synonyms: N-803 COMPONENT IL-15R.ALPHA.SU/FC FUSION PROTEIN, IGHG1*01, HINGE (71-80), CH2 (81-190), CH3 (191-2Alferminogene tadenovec
go.drugbank.com/drugs/DB05306InvestigationalAlferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease … Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration from a standard
Synonyms: Ad5FGF-4Colchiceine
go.drugbank.com/drugs/DB15534ApprovedColchiceine is one of several metabolites of the anti-gout medication [colchicine].[A192714]
Synonyms: O-Demethylcolchicine, 10-O-demethylcolchicineGuanosine-5'-Diphosphate
go.drugbank.com/drugs/DB04315ExperimentalA guanine nucleotide containing two phosphate groups esterified to the sugar moiety. [PubChem]
Synonyms: Guanosine-5'-DiphosphateRTA 744
go.drugbank.com/drugs/DB05920InvestigationalRTA 744 is a novel anthracycline derivative that crosses the blood-brain barrier and shows significant potential for the treatment of primary and metastatic brain cancers. … Anthracyclines are one of the most broadly used and effective classes of cancer therapies; however, they are not used to treat brain cancers because current therapies do not cross the blood-brain barrier